QGEN - Earnings announcements

Sample technologies, QIAcuity and QDI deliver solid growth; QuantiFERON sales affected by significantly lower immigration testing demand QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced preliminary results for the first quarter of 2026, continuing to deliver strong profitability as adjusted diluted earnings per share (EPS) achieved the outlook. Sales trends were mixed, as lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid growth in other areas of the portfolio. For Q1 2026, preliminary net sales were $492 million, up 2% on a reported basis and down 1% at constant exchange rates (CER) compared with the outlook for at least 1% CER g

Q4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.62 Net sales growth of 1% CER ahead of outlook for steady results vs. Q4 2024, adjusted diluted EPS of $0.62 CER ahead of outlook of about $0.60 CER FY 2025: Net sales of $2.09 billion (+6% at actual rates, +5% CER) at high end of outlook for 4-5% CER growth, adj. diluted EPS of $2.40 CER ahead of outlook of about $2.38 CER Growth pillars on target and deliver $1.49 billion CER of sales with 8% CER growth Adjusted operating income margin at 29.5%, rises 80 basis points from 2024 despite tariffs and currency headwinds 2026 out

QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the fourth quarter of 2025. Press release date / time: Wednesday, February 4 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, February 5, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 769 9200 UK: +44 (0)20 7769 6464 GER: +49 (0)69 254 99300 Conference ID: 3382302 To avoid waiting time, please join the even

Q3 2025 results: Net sales of $533 million (+6% at actual rates); diluted EPS $0.60 Core sales +6% CER (constant exchange rates) driven by QIAstat-Dx (+11% CER), QuantiFERON (+11% CER) and Sample technologies (+3% CER) Solid adjusted operating income margin at 29.6% Adjusted diluted EPS $0.61 ($0.61 CER), above outlook for at least $0.58 CER Ongoing strong operating cash flow of $165 million Full-year 2025 outlook reaffirmed for net sales growth of about 4-5% CER (about 5-6% CER core sales) and raises adj. diluted EPS target to about $2.38 CER Acquisition of Parse Biosciences expands Sample technologies portfolio into the single-cell market, capturing AI-driven growth opportu

QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025. Press release date / time: Tuesday, November 4, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Wednesday, November 5, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 929 477 0402 UK: +44 (0)330 165 3655 GER: +49 (0)69 6610 2480 Conference ID: 3763132 To avoid waiting time, please join the event

Q2 2025 results: Net sales of $534 million (+7% actual rates); adjusted diluted EPS of $0.60 Net sales +6% CER (constant exchange rates) above outlook for at least +5% CER and adjusted diluted EPS of $0.62 CER above outlook for at least $0.60 CER 29.9% adj. operating income margin up 1.5 percentage points vs. 28.4% in Q2 2024 Diagnostic solutions sales +11% CER, driven by QIAstat-Dx (+41% CER) and QuantiFERON (+11% CER) and companion diagnostic partnerships 2025 net sales outlook increased to +4-5% CER (prior about +4% CER) and +5-6% CER core sales (prior about +5% CER); adj. diluted EPS outlook reaffirmed for about $2.35 CER QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standar

QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2025. Press release date / time: Tuesday, August 5, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Wednesday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 929 477 0402 UK: +44 (0)330 165 3655 GER: +49 (0)69 6610 2480 Conference ID: 1992038 To avoid waiting time, please join the event co

Q1 2025 results confirm preliminary announcement: Net sales of $483 million (+5% actual rates, +7% constant exchange rates, CER); adjusted diluted EPS of $0.55 Net sales growth of +7% CER ahead of outlook for about +3% CER growth and adjusted diluted EPS of $0.56 CER ahead of outlook for at least $0.50 CER 29.8% adj. operating income margin up 4.1 percentage points vs. 25.7% in Q1 2024 Operating cash flow of $140 million in Q1 2025 vs. $133 million in Q1 2024 Proposal at Annual General Meeting to introduce a dividend as expansion of capital allocation strategy, also seek authorization for a new $500 million share repurchase Stephen H. Rusckowski proposed to become new Chairman

QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, May 7, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, May 8, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 828 8193 UK: +44 (0)330 165 3655 GER: +49 (0)69 6610 2480 Conference ID: 5803222 To avoid waiting time, please join the event conference 5-10 minute

Q4 2024: Net sales of $521 million (+2% actual rates, +4% constant exchange rates (CER) core growth); diluted EPS of $0.39 and adjusted diluted EPS of $0.61 Net sales of $525 million CER ahead of outlook for at least $520 million CER and adjusted diluted EPS of $0.61 CER ahead of outlook for at least $0.60 CER QIAstat-Dx, QuantiFERON and QIAcuity digital PCR continue double-digit growth pace 30.6% adj. operating income margin up 2.6 percentage points vs. 28.0% in Q4 2023 FY 2024: Exceeded outlook for sales and adj. EPS; adj. operating income margin improves 1.8 percentage points to 28.7% Free cash flow rises 63% to $506 million 2025 outlook for about 4% CER sales grow

QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter 2024. Press release date / time: Wednesday, February 5, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, February 6, at 16:00 Frankfurt time / 15:00 London time / 10:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 828 8193 UK: +44 (0)330 165 4027 GER: +49 (0)69 6610 2480 Conference ID: 9237018 To avoid waiting time, please join the event confer

Venlo, the Netherlands, Nov. 06, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced results for the third quarter and first nine months of 2024. Net sales rose 5% to $502 million in Q3 2024 over Q3 2023, while results at constant exchanges rates (CER) of $502 million rose 6% and were above the outlook for at least $495 million CER. The adjusted operating income margin rose three percentage points to 29.6% on benefits from the recent decision to discontinue the NeuMoDx system as well as broader efficiency gains that have improved profitability and freed up resources for targeted reinvestment. Adjusted diluted earnings per share (EPS) were $0

Venlo, The Netherlands, Oct. 10, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the third quarter 2024. Press release date / time: Wednesday, November 6, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, November 7, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.  Three options for joining the conference call Register for call back connection - Click here: Connect meService is available 15 minutes before the call starts Dial-in by phone U.S.: +1 929 477 0448UK: +44 (0)330 165 3655GER: +49 (0)69 6610 2492Conference ID:

Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and increasing adjusted earnings per share (EPS) to a range of $0.08 - $0.12.1 _________________________1 The company does not forecast GAAP EPS because it cannot predict certain elements that are include

Venlo, the Netherlands, July 31, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced results for the second quarter and first half of 2024. Net sales were stable at $496 million in Q2 2024 compared to Q2 2023, while results at constant exchanges rates (CER) of $502 million rose 1% and were above the outlook for at least $495 million CER. The adjusted operating income margin rose about one percentage point to 28.4% from Q2 2023 on efficiency gains while supporting targeted investments. Adjusted diluted earnings per share (EPS) were $0.55, and results at CER of $0.55 were above the outlook for at least $0.52 CER. QIAGEN has updated its FY

Venlo, The Netherlands, July 02, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the second quarter 2024. Press release date / time: Wednesday, July 31, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, August 1, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect meService is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 828 8193UK: +44 (0)330 165 3655GER: +49 (0)69 6610 2492Conference ID: 8081

Venlo, the Netherlands, April 29, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced results for the first quarter of 2024. Net sales declined 5% to $459 million, while results at constant exchanges rates (CER) of $462 million were above the outlook for at least $455 million CER. The adjusted operating income margin rose to 25.7% from 25.6% in the year-ago period on realized efficiency gains while supporting investments into the portfolio. Adjusted diluted earnings per share (EPS) were $0.46, and results at CER were $0.47 and above the outlook for at least $0.44 CER. For 2024, QIAGEN has reaffirmed its outlook for net sales of at least

Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024. Press release date / time: Monday, April 29, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Tuesday, April 30, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.  Three options for joining the conference call Register for call back connection - Click here: Connect meService is available 15 minutes before the call starts  Dial-in by phone U.S.: +1 646 828 8193UK: +44 (0)330 165 3655GER: +49 (0)69 6610 2492Conference ID: 2903795To avoid

Venlo, the Netherlands, Feb. 06, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) announced results for the fourth quarter and full-year 2023. Net sales results of $503 million at constant exchange rates (CER) for Q4 2023 achieved the outlook for at least $500 million CER, driven by 8% CER growth in the non-COVID-19 portfolio. Total sales for Q4 2023 rose 2% (+1% CER) to $509 million from Q4 2022, a period marked by significant COVID-19 sales. Adjusted diluted earnings per share (EPS) were $0.55 CER and above the outlook for at least $0.53 CER. Full-year 2023 sales declined 8% to $1.97 billion, achieving the outlook for $1.97 billion CER sales and were

Venlo, The Netherlands, Jan. 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter and full year 2023. Press release date/time: Tuesday, February 6, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date/time: Wednesday, February 7, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.  Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts  Dial-in by phone U.S.: +1 646 828 8193UK: +44 (0)330 165 3655GER: +49 (

Venlo, the Netherlands, Oct. 30, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) announced results for the third quarter and first nine months of 2023. Net sales results of $470 million at constant exchange rates (CER) for Q3 2023 were above the outlook for at least $465 million CER, driven by 5% CER growth in the non-COVID-19 portfolio. Overall sales results for Q3 2023 declined 5% (-6% CER) to $476 million from Q3 2022, a period marked by significant COVID-19 sales contributions. Adjusted diluted earnings per share (EPS) were $0.50, and results of $0.50 CER were above the outlook for at least $0.48 CER. QIAGEN has reaffirmed its full-year 2023 outlook

Venlo, the Netherlands, Oct. 09, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023. Press release date / time: Monday, October 30, shortly after 21:05 Frankfurt time / 20:05 London time / 16:05 New York time. (For Europe: Due to the U.S. time switch, our Press release will be published one hour earlier than usual.) Conference call date / time: Tuesday, October 31, at 14:00 Frankfurt time / 13:00 London time / 09:00 New York time. (For Europe: Due to the U.S. time switch, our conference call will be held one hour earlier than usual.) Three options for joining the conference call

Venlo, the Netherlands, Aug. 08, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) announced results for the second quarter and first half of 2023. Net sales results of $497 million at constant exchange rates (CER) for Q2 2023 were above the outlook for at least $490 million CER, driven by 9% CER growth in the non-COVID-19 portfolio. Overall sales results for Q2 2023 declined 4% (-4% CER) to $495 million from Q2 2022, a period marked by significant COVID-19 sales. Adjusted diluted earnings per share (EPS) were $0.51, and results of $0.52 CER were above the outlook for at least $0.50 CER. QIAGEN has revised its full-year 2023 outlook for net sales of at le

Venlo, The Netherlands, July 24, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the second quarter 2023. Press release date / time: Tuesday, August 8, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Wednesday, August 9, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.  Three options for joining the conference call 1.Register for call back connection - Click here: Connect meService available 15 minutes before call start  2. Dial-in by phone U.S.: +1 646 828 8193UK: +44 (0)330 165 3655GER: +49 (0)69 6610 2490Conference ID: 4

Venlo, the Netherlands, May 03, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) announced results for the first quarter of 2023. Net sales for Q1 2023 declined 23% (-20% at constant exchange rates, CER) to $485 million from Q1 2022, which was marked by very strong COVID-19 sales contributions. However, the CER sales results of $502 million for Q1 2023 were above the outlook for at least $490 million CER, and driven by 12% CER growth in the non-COVID-19 portfolio. COVID-19 product group sales fell 76% CER  amid significantly reduced demand compared to the year-ago period. Adjusted diluted earnings per share (EPS) were $0.51 ($0.52 CER), ahead of the outlook f

Q4 2022: Net sales of $498 million (-14% at actual rates, -9% at constant exchange rates, CER); diluted EPS of $0.39 and adjusted diluted EPS of $0.53 Net sales at CER of $531 million vs. outlook for at least $520 million CER, adjusted diluted EPS of $0.55 CER vs. outlook for at least $0.50 CER 15% CER growth in non-COVID product portfolio to $432 million Full-year 2022: Net sales decline 5% (0% CER) to $2.14 billion; diluted EPS of $1.84 and adjusted diluted EPS of $2.38 ($2.46 CER) - results exceed outlook 14% CER growth in non-COVID product portfolio to $1.67 billion Operating cash flow rises 12% to $715 million; free cash flow up 30% to $586 million 2023 outlook initiat

QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the fourth quarter and full-year 2022. Press release date / time: Tuesday, February 7, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Wednesday, February 8, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection   Click here: Connect me   Service available 15 minutes before call start Dial-in by phone     +1 646 828 8193 (U.S.) +44 (0)330 165 3655 (UK) +49 (0)69 2222 25574 (GER)   To avoid waiting time, please joi

Q3 2022: Net sales of $500 million (-7% at actual rates, 0% at constant exchange rates, CER); diluted EPS of $0.36 and adjusted diluted EPS of $0.53 Net sales at CER of $533 million vs. outlook for at least $510 million CER, adjusted diluted EPS of $0.55 CER vs. outlook for at least $0.48 CER 18% CER growth in non-COVID product portfolio to $417 million First nine months 2022 operating cash flow up 34% to $591 million, while free cash flow advances 67% to $504 million on strong business expansion 2022 sales outlook raised to about $2.25 billion CER, reaffirmed double-digit CER growth in non-COVID products; adj. diluted EPS outlook raised to about $2.40 CER QIAGEN N.V. (NYSE:QGE

QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter of 2022. Press release date / time: Monday, November 7, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Tuesday, November 8, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection   Click here: Connect me   Service available 15 minutes before call start Dial-in by phone     +1 646 828 8073 (U.S.) +44 (0)330 165 4012 (UK) +49 (0)69 22222 5197 (GER)   To avoid waiting time, please join the event c

Q2 2022: Net sales of $516 million (-9% actual rates, -4% CER); diluted EPS of $0.42 and adjusted diluted EPS of $0.51 over year-ago period Net sales of $544 million at CER vs. outlook for at least $510 million CER, adjusted diluted EPS of $0.53 CER vs. outlook for at least $0.46 CER Non-COVID sales rise 10% CER to $423 million, and up 15% CER excluding Q2 2021 genomics technology sale; COVID-19 sales decline 39% CER H1 2022 operating cash flow +33% to $379 million, free cash flow +63% to $318 million 2022 net sales outlook raised to at least $2.2 billion CER, reaffirmed double-digit CER growth in non-COVID products; adj. diluted EPS outlook raised to at least $2.30 CER QIAGE

QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the second quarter of 2022. Press release date / time: Wednesday, July 27, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, July 28, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection   Click here: Connect Me   Service available 15 minutes before call start Dial-in by phone     +1 646 828 8075 (U.S.) +44 (0)330 165 4012 (UK) +49 (0)69 22222 5197 (GER)   To avoid waiting time, please join the event co

Q1 2022: Net sales rise 11% (+15% constant exchange rates, or CER) to $628.4 million vs. outlook for at least 7% CER growth; diluted EPS of $0.67 and adjusted diluted EPS of $0.80 ($0.83 CER) vs. outlook for at least $0.72 CER 14% CER rise in non-COVID sales, while COVID-19 sales grow 18% CER Operating cash flow rises 61% to $207 million, free cash flow increases 116% to $178 million 2022 net sales outlook raised to at least $2.12 billion CER, reaffirmed double-digit CER growth in non-COVID products; adj. diluted EPS outlook raised to at least $2.14 CER QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) announced results for the first quarter of 2022 and increased the outl

QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release results for the first quarter of 2022 on Wednesday, April 27, at approximately 22:05 Frankfurt time / 21:05 London time / 16:05 New York time Call date/time: Thursday, April 28, at 16:00 Frankfurt time / 15:00 London time / 10:00 New York time. Hosts: Thierry Bernard, Chief Executive Officer, and Roland Sackers, Chief Financial Officer. Three options for joining the call         Register for call back connection   Click here: Connect Me     Service available 15 minutes before call start Dial-in by phone     +1 929 477 0402 (U.S.) +44 (0)330 165 3655 (UK

Q4 2021: Net sales grow 2% (+4% constant exchange rates, or CER) to $582 million and adjusted diluted EPS rises 9% to $0.74 ($0.75 CER) - both above outlook Full-year 2021: Net sales grow 20% (+19% CER) to $2.25 billion and adjusted diluted EPS rises 23% to $2.65 ($2.63 CER) - both above outlook 22% CER growth in non-COVID product sales, ahead of target for 20% CER Operating cash flow grows 40% to $639 million, free cash flow rises 38% to $449 million QIAGEN initiates 2022 outlook for at least $2.07 billion net sales CER, including double-digit CER growth in non-COVID products vs. 2021, and adjusted diluted EPS of at least $2.05 CER QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Stand

QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the fourth quarter and full-year results of 2021 on Tuesday, February 8, at approximately 16:05 Eastern Standard Time (EST) / 22:05 Central European Time (CET). A conference call is scheduled for Wednesday, February 9 at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. It will be hosted by Thierry Bernard, Chief Executive Officer, and Roland Sackers, Chief Financial Officer. Conference call and webcast details Please use the following link to have the conference call you: Connect Me. This „click to join function" will be available 15 minutes before the

Q3 2021: Net sales rise 11% (+10% constant exchange rates, CER) to $535 million and adjusted diluted EPS unchanged at $0.58 ($0.58 CER) from Q3 2020, both well above outlook Non-COVID product group sales grow 17% CER to $376 million building on excellent H1 2021 trends, COVID-19 product group sales decline 4% CER to $159 million 9M 2021: Net sales grow 28% (+25% CER) to $1.67 billion, non-COVID sales rise 27% CER to $1.15 billion; adjusted diluted EPS of $1.91 ($1.88 CER) 9M 2021: Operating cash flow up 134% to $441 million, free cash flow up 198% to $302 million Full-year 2021: Outlook upgraded to reflect stronger-than-expected Q3 2021 results, net sales now expected to grow at

QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the third quarter and first nine months of 2021 on Wednesday, November 3, at approximately 21:05 Central European Time (CET) / 16:05 Eastern Daylight Time (EDT). A conference call is scheduled for Thursday, November 4 at 14:30 Frankfurt time /13:30 London time/ 9:30 New York time. It will be hosted by Thierry Bernard, Chief Executive Officer, and Roland Sackers, Chief Financial Officer. (For Europe: Due to the U.S. time switch, the timing of our investor conference call will be held 30 minutes earlier than usual.) Conference call and webcast details Interested partie